Correlation of CRP and Serum Level of Fibrinogen with Severity of Disease in Chronic Obstructive Pulmonary Disease Patients
Med Arh. 2012; 66(3): 159-160
Background and objectives: Data of a previously published study have shown that Chronic Obstructive Pulmonary Disease (COPD) patients have increased serum levels of CRP and fibrinogen. The aim of this work is to investigate if there was any correlation between inflammation factors and severity of COPD. Design and settings: A case control study conducted on 43 COPD patients and 40 healthy controls. Patients and methods: COPD were selected according to GOLD criteria. Exclusion criteria were acute exacerbation of disease in the past 4 weeks, usage of oral corticosteroids and presence of any comorbidity which could raise level of inflammatory proteins. Control group were healthy individuals. Serum levels of CRP and fibrinogen were measured. Results: The mean serum level of CRP in COPD patients was significantly higher than that of controls (p=0.03). No significant difference was found in the mean serum level of fibrinogen between cases and controls. Also, there were no significant correlation between the serum level of CRP or fibrinogen and severity of the disease and arterial O2 saturation. Conclusion: According to our study results, COPD, per se, can increase serum CRP level. Attenuation of systemic inflammation may offer new perspectives in the management of COPD and its comorbidities.
1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J; Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis, management, and prevention of COPD: GOLD executive summary. Am J Respir Crit Care Med. 2007; 176: 532–555.
2. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax. 2006; 61 (1): 17-22.
3. Fabbri LM, Ferrari R. Chronic disease in the elderly: back to the future of internal medicine. Breathe. 2006; 3: 40-49.
4. Agusti A. Thomas A. Neff lecture. Chronic obstructive pulmonary disease: a systemic disease. Proc Am Thorac Soc. 2006; 3: 478–481.
5. Cracowski JL, Yaici A, Sitbon O, Reynaud-Gaubert M, Renversez JC, Pison C, et al. Biomarkers as prognostic factors in pulmonary arterial hypertension. Rationale and study design. Rev Mal Respir. 2004; 21(6 Pt 1): 1137- 1143.
6. Eliasson M. The epidemiology of fibrinogen and fibrinolysis. Determinants of plasma fibrinogen levels and fibrinolytic variables in the population of northern Sweden. Umeå: Umeå University Medical Dissertations; 1995: 42-54.
7. Lind P, Engström G, Stavenow L, Janzon L, Lindgärde F, Hedblad B. Risk of myocardial infarction and stroke in smokers is related to plasma levels of inflammation-sensitive proteins. Arterioscler Thromb Vasc Biol. 2004 Mar; 24(3): 577-582
8. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 164: 1008-1011.
9. Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, Maccallum PK, Wedzicha JA. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005 Oct; 128(4): 1995-2004.
10. Ferroni P, Basili S, Martini F, Vieri M, Labbadia G, Cordova C, Alessandri C, Gazzaniga PP. Soluble P-selectin as a marker of platelet hyperactivity in patients with chronic obstructive pulmonary disease. J Investig Med. 2000; 48: 21-27.